

PuriCore Interim Management Statement

Third Quarter sales up 120%

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, October 13, 2008 — [PuriCore](#) plc (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued an Interim Management Statement covering the three-month and nine-month periods ending September 30, 2008.

Financial Results

- Q3 sales of \$8.4 million (2007: \$3.8 million), an increase of 120% (123% increase at constant currency)
 - US Food Safety revenue increased 162% to \$5.3 million
 - UK Endoscopy revenue increased 79% to \$3.0 million (85% at constant currency)
- Sales for the nine months ending September 30 of \$27.9 million (2007: \$13.8 million), an increase of 103% (104% increase at constant currency)
 - US Food Safety revenue increased 179% to \$16.2 million
 - UK Endoscopy revenue increased by 49% to \$11.4 million (51% at constant currency)
- Cash of \$27.2 million at period end (including the \$9.7 million debt referred to below)

Q3 Operational Highlights

- \$8.6 million contract extension awarded from largest existing Sterilox Food Safety customer, a top-five US supermarket ([announced](#) 2 July)
- \$2.5 million contract extension awarded from another major Sterilox Food Safety customer ([announced](#) 30 July)
- £8.4 million equity (gross) raised in a Placing and an Open Offer ([announced](#) [30 July](#) and [22 August](#))
- \$9.7 million raised through issuance of debt ([announced](#) 1 October)

Outlook

PuriCore remains on track for significant top-line organic growth in 2008 and continuing improvement in margins. Additionally with tight operating expense controls in place, the Company anticipates operational leverage with costs being maintained below prior year levels for the full year.

Greg Bosch, Chief Executive of PuriCore, said:

“PuriCore continues its strong performance with record revenues in both our US Food Safety and UK Endoscopy businesses. Our focus on increasing revenue and controlling operating expenses combined with our recent successful equity and debt fund raisings strengthens our balance sheet and leaves us well-positioned to deliver our business plan.”

About PuriCore

[PuriCore](#) plc (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company’s patented, proprietary technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobacter pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Contacts:

Jennifer Guinan	Greg Bosch, CEO
Sage Strategic Marketing	Darren Weiss, VP Finance
610.410.8111	PuriCore
Jennifer@sagestrat.com	484.321.2700

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All 2008 financials are unaudited.